Laurus Labs Limited

rs,

ctober 23, 2025 To To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 The Listing Department National Stock Exchange of India Ltd., Ex

₹ 3,223

2025 3 1 Corporate Overview Q2 & H1 FY 2026 4 Executive Summary • Strong H1 performance ; ₹ 3,223 Cr Revenues and 33% revenues growth • Multiple CDMO programs in execution covering complex che

33%

erview Q2 & H1 FY 2026 4 Executive Summary • Strong H1 performance ; ₹ 3,223 Cr Revenues and 33% revenues growth • Multiple CDMO programs in execution covering complex chemistries, supported

₹ 818

ltiple CDMO programs in execution covering complex chemistries, supported by Generics growth • ₹ 818 Cr EBITDA resulted in a margin of 25.4%, increased by 10.8% pts, due to improving operational execu

25.4%

ng complex chemistries, supported by Generics growth • ₹ 818 Cr EBITDA resulted in a margin of 25.4%, increased by 10.8% pts, due to improving operational execution • Delivered significant Gross ma

10.8%

ies, supported by Generics growth • ₹ 818 Cr EBITDA resulted in a margin of 25.4%, increased by 10.8% pts, due to improving operational execution • Delivered significant Gross margins expansion of ov

4.5%

s, due to improving operational execution • Delivered significant Gross margins expansion of over 4.5% pts to 59.6% on healthy business mix • Continued investment into manufacturing network expansio

59.6%

oving operational execution • Delivered significant Gross margins expansion of over 4.5% pts to 59.6% on healthy business mix • Continued investment into manufacturing network expansion and capabili

15%

ued investment into manufacturing network expansion and capabilities to drive growth with CAPEX at 15% of sales © 2025 Laurus Labs Ltd. Q2 & H1 - FY26 Results Presentation 23/10/2025 5 Other Q2 M

rs 532

in Pharma manufacturing & R&D investments focused across scale / technology over next several years 532 Acres of Land allotted; 2x bigger than existing land infrastructure >US $600mn of Investment pr

2x

stments focused across scale / technology over next several years 532 Acres of Land allotted; 2x bigger than existing land infrastructure >US $600mn of Investment proposed over next 8 years

rs 6,350

2x bigger than existing land infrastructure >US $600mn of Investment proposed over next 8 years 6,350 Employment opportunity over next 8 years Strategic Investment of US $2mn in Aarvik Therapeutics: